الفهرس 
Aim of the study
Chapter II: Type III Secretion systemOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
P. aeruginosa is one of the most clinically important bacteria. It can cause serious pulmonary, burn, wound and urinary tract infections. Drug resistance and virulence factors are two key factors for the colonization of P. aeruginosa in settings with high antibiotic pressure, such as hospitals, and the development of hospital-acquired infections.
The global threat of nosocomial multidrug-resistant P. aeruginosa is a growing concern among hospitalized patients. Infections caused by P. aeruginosa are severe and often associated with high mortality and morbidity rates. The most important virulence factor is type III secretion system (T3SS) that plays a main role in tissue lysis, bacterial invasion and poor clinical outcome.
The aim of this study was to detect the antimicrobial susceptibility patterns among clinical isolates of P. aeruginosa, and to evaluate the prevalence of T3SS virulence genes (exoS, exoT, exoU and exoY) among these isolates.
This study was performed in Clinical Pathology Department, Faculty of Medicine, Menoufia University. Clinical samples were collected and processed according to standard microbiological methods.
A total of 100 P. aeruginosa isolates were obtained and identified from non-repetitive patients’ specimens, including burn (n=28), blood (n = 16), wound (n = 21), urine (n = 14), sputum (n = 8), endotracheal aspirate (n=1), bed ulcer (n=6), ascitic fluid (n=2) and central venous catheter (n=4). Of these 100 P. aeruginosa isolates, 54 (54%) were obtained from males and 46 (46%) from females with a mean age of 36.99±23.84 years old, ranging from 3 month to 86 years old. Patients used antibiotic (83%), exposed to invasive procedures (68%) and had associated co-morbidities (54%).
Antibiotic susceptibility test results demonstrated that P. aeruginosa isolates showed the highest resistance against ceftazidime (82%), followed by gentamycin (74%), amikacin (66%), piperacillin-tazobactam, cefepime, levofloxacin (63% for each), ciprofloxacin (59%), meropenem (56%) and imipenem (54%). The highest frequency of resistance was observed with ceftazidime while the highest frequency of sensitivity was observed with imipenem and meropenem. Of the 100 tested P. aeruginosa isolates, 64 (64%) isolates were MDR.